In a report released on September 30, Evan Seigerman from BMO Capital assigned a Buy rating to BioNTech SE, with a price target of $143.00. The company’s shares closed yesterday at $102.21.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Seigerman is a 3-star analyst with an average return of 3.6% and a 45.90% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Bristol-Myers Squibb, and Eli Lilly & Co.
In addition to BMO Capital, BioNTech SE also received a Buy from Bank of America Securities’s Tazeen Ahmad in a report issued yesterday. However, on September 22, J.P. Morgan maintained a Hold rating on BioNTech SE (NASDAQ: BNTX).
The company has a one-year high of $129.27 and a one-year low of $81.20. Currently, BioNTech SE has an average volume of 881K.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.
Read More on BNTX:
Disclaimer & DisclosureReport an Issue
- BioNTech SE: Strategic AI Integration and Innovations Drive Buy Rating
- BioNTech Hosts Second AI Day to Showcase AI Integration
- BioNTech price target raised to $121 from $116 at JPMorgan
- CDC panel votes against requiring prescriptions for Covid shots, Bloomberg says
- Pfizer, BioNTech express dedication to making safe Covid vaccines
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)
